Tyloxapol

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Tyloxapol
Tyloxapol.png
Systematic (IUPAC) name
formaldehyde;oxirane;4-(2,4,4-trimethylpentan-2-yl)phenol
Clinical data
AHFS/Drugs.com International Drug Names
Identifiers
25301-02-4 YesY
R05CA01
PubChem CID 71388
DrugBank DB06439 N
ChemSpider 11052515 N
UNII Y27PUL9H56 N
KEGG D03261 N
ChEMBL CHEMBL1201548 N
Chemical data
Formula (C15H21O(C2H4O)m)n
variable
 N (what is this?)  (verify)

Tyloxapol is a nonionic liquid polymer of the alkyl aryl polyether alcohol type. It is used as a surfactant to aid liquefaction and removal of mucopurulent[citation needed] (containing mucus and pus) bronchopulmonary secretions,[1][2] administered by inhalation through a nebulizer[3] or with a stream of oxygen.

With intraperitoneal injection, tyloxapol also blocks plasma lipolytic activity, and thus the breakdown of triglyceride-rich lipoproteins. This mechanism is used to induce experimental hyperlipidemia in animals.[4]

Tyloxapol is the main active ingredient of the medical device Tacholiquin. Tacholiquin is an Expectorant designated for inhalation and instillation reaching the upper and lower airways. Other brand names of pharmaceutical products containing Tyloxpol are: Exosurf, Alevaire

References[edit]

  1. ^ Sehgal, S. S.; Ewing, C. K.; Richards, T.; Taeusch, H. W. (1994). "Modified bovine surfactant (Survanta) versus a protein-free surfactant (Exosurf) in the treatment of respiratory distress syndrome in preterm infants: A pilot study". Journal of the National Medical Association 86 (1): 46–52. PMC 2607653. PMID 8151722.  edit
  2. ^ Rubin, B. K.; Ramirez, O.; King, M. (1992). "Mucus rheology and transport in neonatal respiratory distress syndrome and the effect of surfactant therapy". Chest 101 (4): 1080–1085. doi:10.1378/chest.101.4.1080. PMID 1555424.  edit
  3. ^ Drugs.com: Tyloxapol definition
  4. ^ Kourounakis, A. P.; Victoratos, P.; Peroulis, N.; Stefanou, N.; Yiangou, M.; Hadjipetrou, L.; Kourounakis, P. N. (2002). "Experimental hyperlipidemia and the effect of NSAIDs". Experimental and molecular pathology 73 (2): 135–138. doi:10.1006/exmp.2002.2449. PMID 12231215.  edit